Earnings To Watch Arcutis Biotherapeutics Inc Reports Q3 2024 Result
| ARQT Stock | USD 13.98 0.32 2.34% |
Slightly above 54% of Arcutis Biotherapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Arcutis Biotherapeutics suggests that some traders are interested. Arcutis Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Arcutis Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Arcutis Biotherapeutics Inc is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is 37.62 million, and the
Read at gurufocus.com
 |
Arcutis Biotherapeutics Fundamental Analysis
We analyze Arcutis Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Arcutis Biotherapeutics is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Arcutis Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcutis Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Arcutis Biotherapeutics Related Equities
| TERN | Terns Pharmaceuticals | 2.72 | ||||
| SPRO | Spero Therapeutics | 1.45 | ||||
| ERAS | Erasca | 0.83 | ||||
| INZY | Inozyme Pharma | 0.25 | ||||
| MIRM | Mirum Pharmaceuticals | 0.11 | ||||
| DAWN | Day One | 0.32 | ||||
| AMLX | Amylyx Pharmaceuticals | 0.93 | ||||
| ABOS | Acumen Pharmaceuticals | 0.97 | ||||
| DSGN | Design Therapeutics | 1.55 | ||||
| APLS | Apellis Pharmaceuticals | 1.91 | ||||
| GLUE | Monte Rosa | 1.98 | ||||
| CHRS | Coherus BioSciences | 2.56 | ||||
| BOLT | Bolt Biotherapeutics | 3.03 | ||||
| XFOR | X4 Pharmaceuticals | 4.02 |
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.